FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252733472> ?p ?o ?g. }

• W4252733472 abstract "Abstract PurposeLarotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or amplification pretreated with one or more system regimens, and to recommend appropriate dose for its further study.MethodsPatients received larotinib orally at 3 doses (250, 300, 350 mg), once daily. Clinical response was evaluated every 8-weeks according to RECIST v1.1 criteria by both investigators and independent radiology review (IRC).Results81 patients were enrolled. The investigator-assessed overall response rate (ORR) was 13.7% (10/73), all responses were observed in the 350 mg group of which ORR up to 20.0% (10/50), with 10 of them having EGFR overexpression and 4 having EGFR amplification. Per IRC assessment, ORR for all patients and 350 mg group were 13.9% (10/72) and 16.3% (8/50). In the 350 mg group, median overall survival (OS) and progression-free survival (PFS) were 8.0 (95% CI, 4.9–10.2) months and 3.4 (95%CI, 2.4–3.7) months, respectively. The most common treatment-related adverse events (TRAEs) were diarrhea, rash and palmar-plantar erythrodysesthesia syndrome, elevated AST/ALT, vomiting, similarly with other EGFR TKIs.ConclusionLarotinib demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.Trial registrationNCT03888092, registered on March 25, 2019, retrospectively registered. https://clinicaltrials.gov/ct2/show/NCT03888092" @default.
• W4252733472 created "2022-05-12" @default.
• W4252733472 creator A5010379353 @default.
• W4252733472 creator A5017001198 @default.
• W4252733472 creator A5021846453 @default.
• W4252733472 creator A5026446568 @default.
• W4252733472 creator A5029076691 @default.
• W4252733472 creator A5031810848 @default.
• W4252733472 creator A5037672730 @default.
• W4252733472 creator A5042630641 @default.
• W4252733472 creator A5042808523 @default.
• W4252733472 creator A5058258474 @default.
• W4252733472 creator A5062159098 @default.
• W4252733472 creator A5062179244 @default.
• W4252733472 creator A5079926306 @default.
• W4252733472 creator A5084686837 @default.
• W4252733472 creator A5084939652 @default.
• W4252733472 creator A5085129889 @default.
• W4252733472 creator A5085748750 @default.
• W4252733472 creator A5087661837 @default.
• W4252733472 creator A5087809584 @default.
• W4252733472 date "2021-05-19" @default.
• W4252733472 modified "2023-09-28" @default.
• W4252733472 title "Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study" @default.
• W4252733472 doi "https://doi.org/10.21203/rs.3.rs-517047/v1" @default.
• W4252733472 hasPublicationYear "2021" @default.
• W4252733472 type Work @default.
• W4252733472 citedByCount "0" @default.
• W4252733472 crossrefType "posted-content" @default.
• W4252733472 hasAuthorship W4252733472A5010379353 @default.
• W4252733472 hasAuthorship W4252733472A5017001198 @default.
• W4252733472 hasAuthorship W4252733472A5021846453 @default.
• W4252733472 hasAuthorship W4252733472A5026446568 @default.
• W4252733472 hasAuthorship W4252733472A5029076691 @default.
• W4252733472 hasAuthorship W4252733472A5031810848 @default.
• W4252733472 hasAuthorship W4252733472A5037672730 @default.
• W4252733472 hasAuthorship W4252733472A5042630641 @default.
• W4252733472 hasAuthorship W4252733472A5042808523 @default.
• W4252733472 hasAuthorship W4252733472A5058258474 @default.
• W4252733472 hasAuthorship W4252733472A5062159098 @default.
• W4252733472 hasAuthorship W4252733472A5062179244 @default.
• W4252733472 hasAuthorship W4252733472A5079926306 @default.
• W4252733472 hasAuthorship W4252733472A5084686837 @default.
• W4252733472 hasAuthorship W4252733472A5084939652 @default.
• W4252733472 hasAuthorship W4252733472A5085129889 @default.
• W4252733472 hasAuthorship W4252733472A5085748750 @default.
• W4252733472 hasAuthorship W4252733472A5087661837 @default.
• W4252733472 hasAuthorship W4252733472A5087809584 @default.
• W4252733472 hasBestOaLocation W42527334721 @default.
• W4252733472 hasConcept C126322002 @default.
• W4252733472 hasConcept C143998085 @default.
• W4252733472 hasConcept C170493617 @default.
• W4252733472 hasConcept C197934379 @default.
• W4252733472 hasConcept C2776694085 @default.
• W4252733472 hasConcept C2777546739 @default.
• W4252733472 hasConcept C2778375690 @default.
• W4252733472 hasConcept C2778496288 @default.
• W4252733472 hasConcept C2778570526 @default.
• W4252733472 hasConcept C2779438470 @default.
• W4252733472 hasConcept C2779802037 @default.
• W4252733472 hasConcept C2779984678 @default.
• W4252733472 hasConcept C2780580376 @default.
• W4252733472 hasConcept C2780852908 @default.
• W4252733472 hasConcept C2994415158 @default.
• W4252733472 hasConcept C31760486 @default.
• W4252733472 hasConcept C71924100 @default.
• W4252733472 hasConcept C90924648 @default.
• W4252733472 hasConceptScore W4252733472C126322002 @default.
• W4252733472 hasConceptScore W4252733472C143998085 @default.
• W4252733472 hasConceptScore W4252733472C170493617 @default.
• W4252733472 hasConceptScore W4252733472C197934379 @default.
• W4252733472 hasConceptScore W4252733472C2776694085 @default.
• W4252733472 hasConceptScore W4252733472C2777546739 @default.
• W4252733472 hasConceptScore W4252733472C2778375690 @default.
• W4252733472 hasConceptScore W4252733472C2778496288 @default.
• W4252733472 hasConceptScore W4252733472C2778570526 @default.
• W4252733472 hasConceptScore W4252733472C2779438470 @default.
• W4252733472 hasConceptScore W4252733472C2779802037 @default.
• W4252733472 hasConceptScore W4252733472C2779984678 @default.
• W4252733472 hasConceptScore W4252733472C2780580376 @default.
• W4252733472 hasConceptScore W4252733472C2780852908 @default.
• W4252733472 hasConceptScore W4252733472C2994415158 @default.
• W4252733472 hasConceptScore W4252733472C31760486 @default.
• W4252733472 hasConceptScore W4252733472C71924100 @default.
• W4252733472 hasConceptScore W4252733472C90924648 @default.
• W4252733472 hasLocation W42527334721 @default.
• W4252733472 hasLocation W42527334722 @default.
• W4252733472 hasOpenAccess W4252733472 @default.
• W4252733472 hasPrimaryLocation W42527334721 @default.
• W4252733472 hasRelatedWork W2037572837 @default.
• W4252733472 hasRelatedWork W2051732006 @default.
• W4252733472 hasRelatedWork W2105212912 @default.
• W4252733472 hasRelatedWork W2243375749 @default.
• W4252733472 hasRelatedWork W2345585868 @default.
• W4252733472 hasRelatedWork W2378568667 @default.
• W4252733472 hasRelatedWork W3162203044 @default.
• W4252733472 hasRelatedWork W4241439418 @default.
• W4252733472 hasRelatedWork W4252733472 @default.
• W4252733472 hasRelatedWork W4253034792 @default.
• W4252733472 isParatext "false" @default.

• next